乳腺癌患者的营养治疗专家共识

2021-08-09 中国抗癌协会肿瘤营养专业委员会 肿瘤代谢与营养电子杂志

乳腺癌作为女性最常见的恶性肿瘤,手术、放化疗、内分泌治疗和靶向治疗是常用的治疗手段。

中文标题:

乳腺癌患者的营养治疗专家共识

发布日期:

2021-08-09

简要介绍:

乳腺癌作为女性最常见的恶性肿瘤,手术、放化疗、内分泌治疗和靶向治疗是常用的治疗手段。越来越多的循证医学证据表明,乳腺癌患者营养状态与疾病治疗效果、复发风险、死亡风险及生活质量等密切相关。适当的营养治疗不仅帮助乳腺癌患者保持良好的营养状态和生活习惯,增加治疗耐受性,改善治疗效果,提高生活质量,而且可以降低乳腺癌患者的复发和死亡风险。乳腺癌患者的营养监测与治疗不容忽视,应当与抗肿瘤治疗并重。相对营养不足而言,乳腺癌患者营养过剩的发生率更高。营养过剩可引起身体损伤、生活质量下降、治疗相关不良反应增加以及持久的心理社会问题等不良后果。乳腺癌确诊后应进行营养风险筛查及营养评估,即使采取有效的营养治疗措施,并且在整个疾病过程中定期进行随访。

相关资料下载:
[AttachmentFileName(sort=1, fileName=乳腺癌患者的营养治疗专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=253951c0022a0494, title=乳腺癌患者的营养治疗专家共识, enTitle=, guiderFrom=肿瘤代谢与营养电子杂志, authorId=0, author=, summary=乳腺癌作为女性最常见的恶性肿瘤,手术、放化疗、内分泌治疗和靶向治疗是常用的治疗手段。, cover=https://img.medsci.cn/20211027/1635339478716_1608702.jpg, journalId=0, articlesId=null, associationId=2054, associationName=中国抗癌协会肿瘤营养专业委员会, associationIntro=中国抗癌协会肿瘤营养专业委员会, copyright=0, guiderPublishedTime=Mon Aug 09 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">乳腺癌作为女性最常见的恶性肿瘤,手术、放化疗、内分泌治疗和靶向治疗是常用的治疗手段。越来越多的循证医学证据表明,乳腺癌患者营养状态与疾病治疗效果、复发风险、死亡风险及生活质量等密切相关。适当的营养治疗不仅帮助乳腺癌患者保持良好的营养状态和生活习惯,增加治疗耐受性,改善治疗效果,提高生活质量,而且可以降低乳腺癌患者的复发和死亡风险。乳腺癌患者的营养监测与治疗不容忽视,应当与抗肿瘤治疗并重。相对营养不足而言,乳腺癌患者营养过剩的发生率更高。营养过剩可引起身体损伤、生活质量下降、治疗相关不良反应增加以及持久的心理社会问题等不良后果。乳腺癌确诊后应进行营养风险筛查及营养评估,即使采取有效的营养治疗措施,并且在整个疾病过程中定期进行随访。</span></p>, tagList=[TagDto(tagId=285, tagName=乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=34, categoryName=全科与营养, tenant=100), CategoryDto(categoryId=66, categoryName=营养科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=285, guiderKeyword=乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12420, appHits=275, showAppHits=0, pcHits=526, showPcHits=12145, likes=2, shares=38, comments=12, approvalStatus=1, publishedTime=Sat Oct 30 21:38:32 CST 2021, publishedTimeString=2021-08-09, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Wed Oct 27 21:06:50 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 22:53:55 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=乳腺癌患者的营养治疗专家共识.pdf)])
乳腺癌患者的营养治疗专家共识.pdf
下载请点击:
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2108032, encodeId=3235210803278, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac395619248, createdName=ms5000001043947570, createdTime=Thu Dec 29 13:44:50 CST 2022, time=2022-12-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1225354, encodeId=8149122535403, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:38:07 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213845, encodeId=00e512138450b, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9e8122147, createdName=ms3000000617731092, createdTime=Sun Apr 24 10:04:30 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184228, encodeId=9c2e118422838, content=太有用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61f25554382, createdName=王思宇, createdTime=Fri Jan 14 14:14:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183132, encodeId=43a7118313267, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31186459233, createdName=糊糊喵, createdTime=Tue Jan 11 10:56:26 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-12-29 ms5000001043947570 来自河北省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2108032, encodeId=3235210803278, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac395619248, createdName=ms5000001043947570, createdTime=Thu Dec 29 13:44:50 CST 2022, time=2022-12-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1225354, encodeId=8149122535403, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:38:07 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213845, encodeId=00e512138450b, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9e8122147, createdName=ms3000000617731092, createdTime=Sun Apr 24 10:04:30 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184228, encodeId=9c2e118422838, content=太有用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61f25554382, createdName=王思宇, createdTime=Fri Jan 14 14:14:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183132, encodeId=43a7118313267, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31186459233, createdName=糊糊喵, createdTime=Tue Jan 11 10:56:26 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-06-09 ms5000000275821148

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2108032, encodeId=3235210803278, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac395619248, createdName=ms5000001043947570, createdTime=Thu Dec 29 13:44:50 CST 2022, time=2022-12-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1225354, encodeId=8149122535403, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:38:07 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213845, encodeId=00e512138450b, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9e8122147, createdName=ms3000000617731092, createdTime=Sun Apr 24 10:04:30 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184228, encodeId=9c2e118422838, content=太有用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61f25554382, createdName=王思宇, createdTime=Fri Jan 14 14:14:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183132, encodeId=43a7118313267, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31186459233, createdName=糊糊喵, createdTime=Tue Jan 11 10:56:26 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-04-24 ms3000000617731092

    好好好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2108032, encodeId=3235210803278, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac395619248, createdName=ms5000001043947570, createdTime=Thu Dec 29 13:44:50 CST 2022, time=2022-12-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1225354, encodeId=8149122535403, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:38:07 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213845, encodeId=00e512138450b, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9e8122147, createdName=ms3000000617731092, createdTime=Sun Apr 24 10:04:30 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184228, encodeId=9c2e118422838, content=太有用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61f25554382, createdName=王思宇, createdTime=Fri Jan 14 14:14:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183132, encodeId=43a7118313267, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31186459233, createdName=糊糊喵, createdTime=Tue Jan 11 10:56:26 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-01-14 王思宇

    太有用了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2108032, encodeId=3235210803278, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac395619248, createdName=ms5000001043947570, createdTime=Thu Dec 29 13:44:50 CST 2022, time=2022-12-29, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1225354, encodeId=8149122535403, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:38:07 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213845, encodeId=00e512138450b, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9e8122147, createdName=ms3000000617731092, createdTime=Sun Apr 24 10:04:30 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184228, encodeId=9c2e118422838, content=太有用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61f25554382, createdName=王思宇, createdTime=Fri Jan 14 14:14:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183132, encodeId=43a7118313267, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31186459233, createdName=糊糊喵, createdTime=Tue Jan 11 10:56:26 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-01-11 糊糊喵

    谢谢分享

    0

拓展阅读

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组(统称) · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2010版)

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议:乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南:乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南:激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12